Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stillen 2X Tab vs Patisren S Tab in Acute or Chronic Gastritis (Phase IV, Non-inferiority)
KCT0012033Phase 4Not yet recruiting
- Sponsor
- Richwood Trading Company
- Start
- Jun 2026
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Stillen, patisiran in gastritis, sponsored by Richwood Trading Company. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Stillenpatisiran
03
Conditions
gastritis
Beyond the preview
Go deeper on KCT0012033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012033.